


Investigating neuronal injury in a HIV cure strategy

Jasmini Alagaratnam
Clinical Research Fellow
Imperial College London


Why can't ART cure HIV? The viral reservoir



HIV reservoir sites

HIV infects CD4+ cells


Some become
resting memory cells;
'reservoir'



Major reservoirs

Dormant memory T cells in
lymph nodes and blood²

Macrophages and
dendritic cells in various
tissues (especially in
lymph nodes, gut and
central nervous system)²



Research into HIV cure has intensified

The NEW ENGLAND JOURNAL of MEDICINE

BRIEF REPORT

Long-Term Control of HIV by CCR5 Delta32/ Delta32 Stem-Cell Transplantation

Gero Hütter, M.D., Daniel Nowak, M.D., Maximilian Mossner, B.S.,
Susanne Ganepola, M.D., Arne Müßig, M.D., Kristina Allers, Ph.D.,
Thomas Schneider, M.D., Ph.D., Jörg Hofmann, Ph.D., Claudia Kücherer, M.D.,
Olga Blau, M.D., Igor W. Blau, M.D., Wolf K. Hofmann, M.D.,
and Eckhard Thiel, M.D.

LETTER

<https://doi.org/10.1038/s41586-01>


HIV-1 remission following CCR5 Δ 32/ Δ 32 haematopoietic stem-cell transplantation

Ravindra K. Gupta^{1,2,3,4,5*}, Sultan Abdul-Jawad¹, Laura E. McCoy¹, Hoi Ping Mok⁴, Dimitra Peppas^{3,6}, Maria Salgado⁷,
Javier Martinez-Picado^{7,8,9}, Monique Nijhuis¹⁰, Annemarie M. J. Wensing¹⁰, Helen Lee¹¹, Paul Grant¹², Eleni Nastouli¹²,
Jonathan Lambert¹³, Matthew Pace⁶, Fanny Salasc⁴, Christopher Monit¹, Andrew J. Innes^{14,15}, Luke Muir¹, Laura Waters³,
John Frater^{6,16}, Andrew M. L. Lever^{4,17}, Simon G. Edwards³, Ian H. Gabriel^{14,15,18,19} & Eduardo Olavarria^{14,15,19}

Data on the safety aspects of HIV cure strategies are limited¹

1. Dubé K. Trends Microbiol. 2014 Oct;22(10):547-9

Kick and kill



Potential CNS risks of 'kick and kill'

1. Direct neuronal injury:

- Viral rebound releasing viral proteins which are neurotoxic
- LRA toxicities

2. Indirect neuronal injury:


- CNS IRIS, CD8+ mediated encephalitis
 - Following HIV vaccines which may modify immune responses
- Inflammation & immune activation
 - Following viral rebound or HIV vaccines

3. Removal of cells with crucial function

4. Reversal of other integrated viruses in a resting phase


CSF Neurofilament Light Chain protein (NFL)

- NFL maintains structure of axons
- Sensitive and dynamic biomarker of active neuroaxonal damage in the CNS
- Elevated concentrations are reported in a variety of neurodegenerative conditions including HIV



Plasma neurofilament light chain (NFL)


- Highly sensitive assay measuring plasma NFL has recently been developed
- Strongly correlates with CSF NFL
- Removes the barriers of repeated CSF sampling
- Allows more frequent measurements




Investigating the impact of kick and kill on neuronal injury

Following ≥ 22
weeks ART

Continue ART
alone



ART + vaccination
+ vorinostat
(ART+V+V)



Methods

Marker measured	Method	Timepoints		
		Week 0 (at randomisation, ≥22 weeks cART)	Week 12 (following completion vaccination and vorinostat)	Week 18
Plasma NFL	Simoa digital immunoassay	✓	✓	✓
Ultra-sensitive HIV RNA	Single-copy assay	✓	✓	✓


Statistical analyses:

- Differences between study arms at each time point
- Changes over time
- Correlations
- Associations with baseline clinical parameters

Results: Baseline demographics

Parameter, median (IQR) or total (%)	n = 58
Age	32 (28 – 40)
Ethnicity	
- White	40 (69)
- Black	4 (7)
- Asian or Hispanic	7 (12)
- Mixed or Other	7 (12)
Mode of HIV acquisition	
- Sex between men	53 (91)
- Heterosexual sex	2(3)
- Unknown	3(5)
Weeks since PHI diagnosis	28 (27 – 37)

Longitudinal changes in plasma NFL



No significant difference in plasma NFL by study arm

Study week		Week 0 (At randomisation)	Week 12 (Following completion of V+V)	Week 18
Plasma NFL, pg/mL¹	ART	7.4 (6.5-8.4)	8.0 (6.6-9.7)	7.1 (6.2-8.0)
	ART+V+V	6.4 (5.4-7.6)	6.9 (5.8-8.1)	6.8 (5.7-8.1)
	<i>P</i> value	0.160	0.218	0.742
Ultra-sensitive HIV RNA, copies/mL²	ART	16.5 (3 – 30)	9 (1 – 14)	5.5 (1 – 20)
	ART+V+V	13 (5 – 23)	5 (1 – 9)	6 (1 – 14)
	<i>P</i> value	0.56	0.21	0.81

1 Geometric mean (95% CI)

2 Median (IQR)

Plasma NFL: Correlations and associations

- Ultra-sensitive HIV RNA:
 - No sig. correlation with plasma NFL seen
- Baseline \log_{10} plasma NFL was associated only with **older age** (0.01 increase per year of age, $p = 0.004$) in multivariate analyses
 - Not associated with ethnicity, duration from seroconversion, mode of HIV acquisition, CD4+ count

Conclusions

- Using plasma NFL as a surrogate marker, we saw **no evidence of neuro-axonal injury following ART+V+V in the RIVER trial**
- Possible reasons for the unchanged plasma NFL concentrations seen:
 - Lack of effect of the intervention on viral transcription in the plasma and on the HIV reservoir in circulating CD4+ T cells
 - Intervention may not have entered the CNS
 - Plasma NFL not sufficiently sensitive
 - Did not capture the neuronal injury episode (measured too early or too late)

Monitoring for CNS adverse events in HIV cure research remains important

Further results being presented at IAS, July 2019

- HIV-specific CD4+ and CD8+ T cell responses in RIVER
 - Correlations with plasma NFL and HIV RNA
 - Monday 22nd July: 12:30pm
 - Abstract number: MOPEB274
-

Acknowledgements

All the RIVER study participants

RIVER Chief Investigator: Sarah Fidler

RIVER co-investigator and laboratory lead: John Frater

RIVER statisticians: Abdel Babiker, Wolfgang Stöhr

RIVER laboratory investigators: Lucy Dorrell, Tom Hanke, Andrew Lever, Myra McClure, Steve Kaye, Matt Pace, Axel Fun, Mikaila Bandara, Maryam Khan, Andrew Lovell, HongBing Yang, Jakub Kopycinski, Natalia Olejniczak, Helen Brown, Nicola Robinson, Otto Erlwein, Alison Crook

RIVER trial management team: Sarah Pett, Rachel Bennett, Michelle Gabriel, Fleur Hudson, Aminata Sy, Adam Gregory, Hanna Box, Cherry Kingsley, Katie Topping, Mary Rauchenberger, Yinka Sowunmi, Shaadi Shidfar, Dominic Hague, Gemma Wood, Charlotte Russell

RIVER clinical investigators: Sarah Fidler, Sabine Kinloch, Sarah Pett, Julie Fox, Amanda Clarke, Mark Nelson, Margaret Johnson

RIVER Trial Steering Committee (TSC): Independent Members: Eric Sandström, Janet Darbyshire, Frank Post, Chris Conlon, Jane Anderson, Mala Maini

RIVER Independent Data and Monitoring Committee (IDMC): Tim Peto, Peter Sasieni, Veronica Miller, Ian Weller

Community of people living with HIV: Simon Collins, Damian Kelly

CHERUB collaboration

Funders: BHIVA, MRC (MRL00528X1), NIHR Imperial BRC, NIHR Oxford BRC, NIHR Cambridge BRC

Industry partners: MSD, GSK

UK Dementia Research Institute, University College London: Henrik Zetterberg, Amanda Heslegrave, Jamie Toombs



Thank you

Questions?

Extra slides

Sterilising Cure

“INFECTIOUS DISEASE” MODEL


- The ‘Berlin’ patient
- Aviraemia; no transmission
- No replication competent virus
- No detectable HIV-infected cells

‘Functional’ Cure

“CANCER” MODEL

- No disease progression
- No CD4 cell loss
- No transmission
- But...no agreed duration

ART alone cannot cure HIV



HIV cure strategies currently being trialled:

Comparison of different strategies for curing HIV					
Approach	Summary	Cost	Scalability	Successes	Comments
Genetic	Altering host genome to resist HIV	\$\$\$	✖	Berlin patient	Unlikely to be a global cure
Kick and kill	Stimulate HIV expression from reservoir, then clearance of HIV expressing cells	\$	✓	HIV expression from reservoir induced using HDACi	2 step approach
Immune based	Alter immune system to clear infected cells	\$??	SIV clearance in Rhesus macaques	May need reservoir stimulation for cure
Early treatment	Start ART in acute infection	\$	✓	Post-treatment controllers	Won't help those with chronic infection

ART: antiretroviral treatment; HDACi: histone deacetylase inhibitors

CSF NFL




Figure 1: CSF NFL vs age in HIV-negative controls




Figure 2: CSF NFL in HIV-positive subjects and HIV-negative controls